| scholarly article | Q13442814 |
| P2093 | author name string | Susanne B Haga | |
| Jivan Moaddeb | |||
| P2860 | cites work | Adverse drug events in hospitalized patients. Excess length of stay, extra costs, and attributable mortality. | Q50979176 |
| Validation of warfarin pharmacogenetic algorithms in clinical practice. | Q50984731 | ||
| Influence of cytochrome P-450 CYP2C9 polymorphisms on warfarin sensitivity and risk of over-anticoagulation in patients on long-term treatment. | Q52106400 | ||
| Current use of pharmacogenetic testing: a national survey of thiopurine methyltransferase testing prior to azathioprine prescription. | Q53574823 | ||
| Usefulness of high clopidogrel maintenance dose according to CYP2C19 genotypes in clopidogrel low responders undergoing coronary stenting for non ST elevation acute coronary syndrome. | Q54356566 | ||
| 2012 ACCF/AHA focused update of the guideline for the management of patients with unstable angina/non-ST-elevation myocardial infarction (updating the 2007 guideline and replacing the 2011 focused update): a report of the American College of Cardiol | Q55056448 | ||
| Pharmacogenomic Testing: Knowing More, Doing Better | Q57817766 | ||
| Frequent distribution of ultrarapid metabolizers of debrisoquine in an ethiopian population carrying duplicated and multiduplicated functional CYP2D6 alleles | Q58003139 | ||
| Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects | Q60018974 | ||
| Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications | Q63241969 | ||
| Pharmacogenetic determination of the effects of codeine and prediction of drug interactions | Q71563655 | ||
| Genetic association between sensitivity to warfarin and expression of CYP2C9*3 | Q73834859 | ||
| Drug use during breastfeeding. A survey from the Netherlands | Q75356116 | ||
| What is clinical utility and why should we care? | Q82475827 | ||
| Discordance between availability of pharmacogenetics studies and pharmacogenetics-based prescribing information for the top 200 drugs | Q83089662 | ||
| Implementation of pharmacogenetics in clinical practice is challenging | Q84947101 | ||
| Academia at the crossroads: education and training in pharmacogenomics | Q88695448 | ||
| Application of a pharmacogenetic test adoption model to six oncology biomarkers | Q88775593 | ||
| CPIC: Clinical Pharmacogenetics Implementation Consortium of the Pharmacogenomics Research Network | Q24632735 | ||
| Evidence-based management of anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines | Q24632951 | ||
| Self-monitoring of oral anticoagulation: systematic review and meta-analysis of individual patient data | Q26865392 | ||
| Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C9 and VKORC1 genotypes and warfarin dosing | Q27008360 | ||
| Human leukocyte antigen class I-restricted activation of CD8+ T cells provides the immunogenetic basis of a systemic drug hypersensitivity | Q27650811 | ||
| Influence of omeprazol on the antiplatelet action of clopidogrel associated to aspirin | Q28200091 | ||
| Clinical significance of the cytochrome P450 2C19 genetic polymorphism | Q28201086 | ||
| Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2 | Q28242581 | ||
| Identification of the gene for vitamin K epoxide reductase | Q28242592 | ||
| Pharmacogenetics of morphine poisoning in a breastfed neonate of a codeine-prescribed mother | Q28258937 | ||
| Codeine intoxication associated with ultrarapid CYP2D6 metabolism | Q28300589 | ||
| Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies | Q29616299 | ||
| Physician barriers to incorporating pharmacogenetic treatment strategies for nicotine dependence into clinical practice | Q30226731 | ||
| Estimation of the warfarin dose with clinical and pharmacogenetic data | Q33410725 | ||
| When is pharmacogenetic testing for antidepressant response ready for the clinic? A cost-effectiveness analysis based on data from the STAR*D study | Q33459789 | ||
| Hypersensitivity reactions during therapy with the nucleoside reverse transcriptase inhibitor abacavir | Q33956146 | ||
| Impact of CYP2C19 variant genotypes on clinical efficacy of antiplatelet treatment with clopidogrel: systematic review and meta-analysis | Q33982372 | ||
| Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study | Q34009506 | ||
| Pharmacogenomic biomarker information in drug labels approved by the United States food and drug administration: prevalence of related drug use. | Q34013022 | ||
| Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy | Q34019082 | ||
| Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir | Q34117815 | ||
| CYP2D6 allele frequency in European Caucasians, Asians, Africans and their descendants | Q34125166 | ||
| Fatal hydrocodone overdose in a child: pharmacogenetics and drug interactions. | Q34137741 | ||
| Allopurinol pharmacogenetics: assessment of potential clinical usefulness | Q34236067 | ||
| Point-of-care genetic testing for personalisation of antiplatelet treatment (RAPID GENE): a prospective, randomised, proof-of-concept trial | Q34264876 | ||
| Cost-effectiveness analysis of HLA B*5701 genotyping in preventing abacavir hypersensitivity | Q34332730 | ||
| Statistical design of personalized medicine interventions: the Clarification of Optimal Anticoagulation through Genetics (COAG) trial | Q34397841 | ||
| Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose | Q34423204 | ||
| The AmpliChip CYP450 genotyping test: Integrating a new clinical tool | Q34537662 | ||
| A population-based study of the drug interaction between proton pump inhibitors and clopidogrel | Q34603772 | ||
| Insurance coverage policies for personalized medicine | Q34608654 | ||
| Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis | Q34624862 | ||
| The impact of pharmacogenomics research on drug development | Q37972982 | ||
| A randomized and clinical effectiveness trial comparing two pharmacogenetic algorithms and standard care for individualizing warfarin dosing (CoumaGen-II). | Q38474432 | ||
| Apnea in a child after oral codeine: a genetic variant - an ultra-rapid metabolizer | Q39334234 | ||
| CYP2C9 genotype-guided warfarin prescribing enhances the efficacy and safety of anticoagulation: a prospective randomized controlled study. | Q40174813 | ||
| Cytochrome P450 2C9 (CYP2C9) and vitamin K epoxide reductase (VKORC1) genotypes as determinants of acenocoumarol sensitivity. | Q40442584 | ||
| Cost impact of prospective HLA-B*5701-screening prior to abacavir/lamivudine fixed dose combination use in Germany | Q42243458 | ||
| Effects of the proton pump inhibitor lansoprazole on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel | Q42646492 | ||
| Multivariate analysis of the relation between diet and warfarin dose. | Q42726687 | ||
| Prospective evaluation of a pharmacogenetics-guided warfarin loading and maintenance dose regimen for initiation of therapy | Q42731228 | ||
| Proton-pump inhibitors are associated with increased cardiovascular risk independent of clopidogrel use: a nationwide cohort study | Q42882409 | ||
| Carriage of cytochrome 2C19 polymorphism is associated with risk of high post-treatment platelet reactivity on high maintenance-dose clopidogrel of 150 mg/day: results of the ACCEL-DOUBLE (Accelerated Platelet Inhibition by a Double Dose of Clopidog | Q42962304 | ||
| Warfarin genotyping reduces hospitalization rates results from the MM-WES (Medco-Mayo Warfarin Effectiveness study). | Q43104385 | ||
| Pharmacogenetic testing in the United Kingdom genetics and immunogenetics laboratories | Q43205615 | ||
| Cost-effectiveness of genotype-guided warfarin dosing for patients with atrial fibrillation | Q43209301 | ||
| A policy model to evaluate the benefits, risks and costs of warfarin pharmacogenomic testing | Q43218793 | ||
| Codeine, ultrarapid-metabolism genotype, and postoperative death | Q43289451 | ||
| Should we be applying warfarin pharmacogenetics to clinical practice? No, not now. | Q43290533 | ||
| Codeine and morphine pathway | Q43480688 | ||
| Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy | Q43942672 | ||
| Pharmacogenetics of neonatal opioid toxicity following maternal use of codeine during breastfeeding: a case-control study | Q44339918 | ||
| Postoperative pain in the neonate: age-related differences in morphine requirements and metabolism | Q44536335 | ||
| Developmental pharmacokinetics of morphine and its metabolites in neonates, infants and young children. | Q44727177 | ||
| Primary care guidelines for the management of persons infected with human immunodeficiency virus: 2009 update by the HIV medicine Association of the Infectious Diseases Society of America | Q45382453 | ||
| Clinical and ethical considerations in pharmacogenetic testing: views of physicians in 3 "early adopting" departments of psychiatry | Q45670133 | ||
| Cost-effectiveness of using pharmacogenetic information in warfarin dosing for patients with nonvalvular atrial fibrillation | Q46157298 | ||
| Effects of pantoprazole and esomeprazole on platelet inhibition by clopidogrel | Q46199177 | ||
| Prospective study of warfarin dosage requirements based on CYP2C9 and VKORC1 genotypes | Q46816940 | ||
| Several-fold increase in risk of overanticoagulation by CYP2C9 mutations | Q46830669 | ||
| Randomized trial of genotype-guided versus standard warfarin dosing in patients initiating oral anticoagulation | Q46910098 | ||
| Extent of medication use in breastfeeding women. | Q46976330 | ||
| HLA-B*5701 clinical testing: early experience in the United States | Q46988876 | ||
| More codeine fatalities after tonsillectomy in North American children | Q48249814 | ||
| Dosing clopidogrel based on CYP2C19 genotype and the effect on platelet reactivity in patients with stable cardiovascular disease | Q34633709 | ||
| Clopidogrel with or without omeprazole in coronary artery disease | Q34660303 | ||
| HLA-B*5701 screening for hypersensitivity to abacavir | Q34747145 | ||
| Executive summary: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). | Q34788509 | ||
| Criteria influencing the clinical uptake of pharmacogenomic strategies | Q34843224 | ||
| Genetic determinants of response to clopidogrel and cardiovascular events | Q34910210 | ||
| Cytochrome p-450 polymorphisms and response to clopidogrel | Q34910228 | ||
| Drug excretion into breast milk--overview | Q35111467 | ||
| Genetics informatics trial (GIFT) of warfarin to prevent deep vein thrombosis (DVT): rationale and study design | Q35218128 | ||
| Outcomes with concurrent use of clopidogrel and proton-pump inhibitors: a cohort study | Q35222839 | ||
| Facilitating clinical implementation of pharmacogenomics | Q35294151 | ||
| Pharmacogenetics of cytochrome p4502D6: genetic background and clinical implication | Q35594563 | ||
| Clinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450-2C19 (CYP2C19) genotype and clopidogrel therapy | Q35603072 | ||
| Introduction to the ninth edition: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines | Q35752615 | ||
| Personalizing medicine with clinical pharmacogenetics | Q35791989 | ||
| The role of cost-effectiveness analysis in the era of pharmacogenomics | Q35817019 | ||
| Maternal medications during breastfeeding | Q35869959 | ||
| Warfarin pharmacogenetics: a rising tide for its clinical value | Q35915581 | ||
| The effect of CYP2D6 polymorphisms on the response to pain treatment for pediatric sickle cell pain crisis | Q35994975 | ||
| Clinical pharmacogenetics implementation consortium guidelines for HLA-B genotype and abacavir dosing | Q36029478 | ||
| Clinical guidelines for psychiatrists for the use of pharmacogenetic testing for CYP450 2D6 and CYP450 2C19. | Q36356462 | ||
| Interethnic differences in genetic polymorphisms of CYP2D6 in the U.S. population: clinical implications | Q36395914 | ||
| Role of cytochrome P450 genotype in the steps toward personalized drug therapy | Q36441521 | ||
| The largest prospective warfarin-treated cohort supports genetic forecasting | Q37071087 | ||
| Pharmacogenetic testing of CYP2C9 and VKORC1 alleles for warfarin | Q37087348 | ||
| High sensitivity of human leukocyte antigen-b*5701 as a marker for immunologically confirmed abacavir hypersensitivity in white and black patients | Q37150304 | ||
| Influence of CYP2C9 and VKORC1 1173C/T genotype on the risk of hemorrhagic complications in African-American and European-American patients on warfarin | Q37195550 | ||
| Optimizing drug outcomes through pharmacogenetics: a case for preemptive genotyping | Q37202877 | ||
| Drug use during breast-feeding | Q37435192 | ||
| Back to the future: why randomized controlled trials cannot be the answer to pharmacogenomics and personalized medicine | Q37551901 | ||
| Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials | Q37590925 | ||
| Clopidogrel pharmacogenomics and risk of inadequate platelet inhibition: US FDA recommendations | Q37627874 | ||
| Using pharmacogenetics in real time to guide warfarin initiation: a clinician update | Q37965130 | ||
| CYP2C19 genotype, clopidogrel metabolism, platelet function, and cardiovascular events: a systematic review and meta-analysis | Q37971875 | ||
| P433 | issue | 4 | |
| P304 | page(s) | 155-169 | |
| P577 | publication date | 2013-08-01 | |
| P1433 | published in | Therapeutic advances in drug safety | Q26853818 |
| P1476 | title | Pharmacogenetic testing: Current Evidence of Clinical Utility | |
| P478 | volume | 4 |
| Q92450459 | Bringing microbiome-drug interaction research into the clinic |
| Q28072203 | Cost-Effectiveness of Pharmacogenomic and Pharmacogenetic Test-Guided Personalized Therapies: A Systematic Review of the Approved Active Substances for Personalized Medicine in Germany |
| Q50117218 | Developing Pharmacogenomic Reports: Insights from Patients and Clinicians. |
| Q54935902 | Disease burden and the role of pharmacogenomics in African populations. |
| Q92875032 | Heterogeneity in the distribution of 159 drug-response related SNPs in world populations and their genetic relatedness |
| Q37063857 | Personalized Medicine in the U.S. and Germany: Awareness, Acceptance, Use and Preconditions for the Wide Implementation into the Medical Standard. |
| Q36508972 | Pharmacogenetics: Using Genetic Information to Guide Drug Therapy |
| Q50333604 | Rapid screening for targeted genetic variants via high-resolution melting curve analysis. |
| Q39833609 | Rare genetic variants in cellular transporters, metabolic enzymes, and nuclear receptors can be important determinants of interindividual differences in drug response |
| Q47929031 | The challenges of implementing pharmacogenomic testing in the clinic. |
Search more.